Kopran Ltd. shows moderate growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it has a relatively low debt level, other companies outperform it in terms of revenue growth and profitability, suggesting a cautious outlook for investors. The peers have varying degrees of valuation, with some companies appearing overvalued, while others present opportunities for value investment.

• • Kopran Ltd. has a moderate revenue growth of 11.54% YoY but underperforms against peers in profitability metrics.
• • Top performers in terms of profitability include Dr. Reddy's Laboratories and Cipla, while Kopran's PE ratio indicates a higher valuation compared to its earnings growth potential.
• • Financially weak companies such as Divi's Laboratories exhibit high PE ratios but poor growth, indicating potential overvaluation.